NASCIMBENI, Fabio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.174
AS - Asia 4.900
EU - Europa 4.401
SA - Sud America 799
Continente sconosciuto - Info sul continente non disponibili 152
AF - Africa 130
OC - Oceania 14
Totale 20.570
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.957
SG - Singapore 1.441
CN - Cina 1.195
IT - Italia 1.123
GB - Regno Unito 1.032
HK - Hong Kong 641
BR - Brasile 586
VN - Vietnam 511
FI - Finlandia 359
DE - Germania 356
SE - Svezia 346
BD - Bangladesh 332
PL - Polonia 264
FR - Francia 208
RU - Federazione Russa 179
IN - India 137
KR - Corea 131
TR - Turchia 113
UA - Ucraina 113
CA - Canada 99
AR - Argentina 74
NL - Olanda 74
BG - Bulgaria 72
ID - Indonesia 70
MX - Messico 54
JP - Giappone 50
IQ - Iraq 45
ZA - Sudafrica 41
ES - Italia 38
EC - Ecuador 33
LT - Lituania 31
IE - Irlanda 30
PK - Pakistan 30
AE - Emirati Arabi Uniti 27
VE - Venezuela 27
BE - Belgio 26
CO - Colombia 23
EG - Egitto 23
RO - Romania 21
UZ - Uzbekistan 21
MY - Malesia 20
SA - Arabia Saudita 20
CH - Svizzera 18
GR - Grecia 18
AT - Austria 17
JO - Giordania 16
PE - Perù 15
CZ - Repubblica Ceca 14
JM - Giamaica 14
PH - Filippine 13
PY - Paraguay 13
AU - Australia 12
CL - Cile 12
DZ - Algeria 12
KE - Kenya 11
MA - Marocco 10
HN - Honduras 9
NP - Nepal 9
SI - Slovenia 9
TN - Tunisia 9
TW - Taiwan 9
UY - Uruguay 9
IL - Israele 8
KZ - Kazakistan 8
RS - Serbia 8
AZ - Azerbaigian 7
BO - Bolivia 7
CR - Costa Rica 7
ET - Etiopia 6
HR - Croazia 6
IR - Iran 6
KG - Kirghizistan 6
MK - Macedonia 6
SV - El Salvador 6
EE - Estonia 5
PT - Portogallo 5
QA - Qatar 5
AL - Albania 4
BY - Bielorussia 4
DO - Repubblica Dominicana 4
GT - Guatemala 4
OM - Oman 4
TT - Trinidad e Tobago 4
BZ - Belize 3
GE - Georgia 3
LB - Libano 3
PS - Palestinian Territory 3
SY - Repubblica araba siriana 3
AO - Angola 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
CG - Congo 2
CI - Costa d'Avorio 2
CY - Cipro 2
DK - Danimarca 2
EU - Europa 2
GH - Ghana 2
HU - Ungheria 2
KW - Kuwait 2
LV - Lettonia 2
Totale 20.381
Salva come PNG Salva come JPEG
Città #
Fairfield 1.102
Ashburn 1.085
Singapore 923
Santa Clara 875
Southend 620
Hong Kong 619
Woodbridge 558
Chandler 470
San Jose 460
Houston 454
Seattle 452
Wilmington 403
Cambridge 348
Hefei 331
Ann Arbor 317
Helsinki 317
Nyköping 268
Warsaw 256
Dearborn 236
Beijing 230
New York 224
London 211
Los Angeles 195
Council Bluffs 188
Ho Chi Minh City 153
Hanoi 125
Modena 124
Jacksonville 121
Chicago 111
Milan 108
Seoul 108
The Dalles 87
San Diego 82
Lauterbourg 70
Rome 67
Sofia 67
Princeton 65
Eugene 62
Buffalo 59
Dallas 57
Munich 56
Izmir 54
São Paulo 54
Shanghai 51
Jakarta 50
Moscow 48
Tokyo 40
Denver 38
Salt Lake City 37
Orem 34
Phoenix 33
Toronto 33
Bologna 32
Frankfurt am Main 32
Boardman 31
Da Nang 28
Chennai 27
Johannesburg 27
Haiphong 26
Poplar 26
Atlanta 25
Bremen 25
Dublin 25
Manchester 25
Nuremberg 25
Redwood City 24
Naples 23
Fremont 22
Biên Hòa 21
Brussels 21
Columbus 21
Tampa 21
Palermo 20
Amsterdam 19
Brooklyn 19
Mexico City 19
Montreal 19
Paris 19
Rio de Janeiro 19
Tashkent 19
Redondo Beach 18
San Mateo 18
Miano 17
Reggio Emilia 17
Schiffdorf 17
Stockholm 17
Baghdad 16
Dong Ket 16
Mumbai 16
Padova 16
Turin 16
Falls Church 15
Parma 15
Timisoara 15
Athens 14
Campinas 14
Norwalk 14
Kent 13
Nanjing 13
Turku 13
Totale 14.106
Salva come PNG Salva come JPEG
Nome #
Terapia antialadosteronica e prevenzione della cardiomiopatia cirrotica 712
Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN) 531
A "systems medicine" approach to the study of non-alcoholic fatty liver disease 496
Prevalence and predictors of liver fibrosis evaluated by vibration controlled transient elastography in type 1 Gaucher disease 406
Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis 391
NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk 375
Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis 367
Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study 364
Fatty liver is associated with an increased risk of diabetes and cardiovascular disease-Evidence from three different disease models: NAFLD, HCV and HIV 339
Statins and nonalcoholic fatty liver disease in the era of precision medicine: More friends than foes 327
Drugs and acute porphyrias: reasons for a hazardous relationship 317
Clinical relevance of liver histopathology and different histological classifications of NASH in adults 317
Hepatocellular carcinoma in a patient treated with efalizumab for psoriasis. 315
ANTIALDOSTERONE THERAPY IN LIVER CIRRHOSIS: A ROLE FOR PREVENTION OF CIRROTHIC CARDIOMIOPATHY? 315
Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. 315
Nonalcoholic fatty liver disease: Evolving paradigms 315
AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions 314
Antialdosterone therapy in liver cirrhosis: a role for prevention of cirrhitc cardiomiopathy ? 313
MTHFR C677T polymorhism and hyperhomocysteinemia in patients with liver cirrhosis complicated by portal vein thrombosis and hepatocellular carcinoma 306
A critical appraisal of the use of ultrasound in hepatic steatosis 305
Do Nonalcoholic Fatty Liver Disease and Fetuin-A Play Different Roles in Symptomatic Coronary Artery Disease and Peripheral Arterial Disease? 301
Synchronous cryptogenic liver cirrhosis and idiopathic pulmonary fibrosis: a clue to telomeres involvement on line pubblication 03-Oct-2012Hepatology- 300
Clinical, biochemical and genetic characteristics of Variegate Porphyria in Italy 294
From NAFLD in clinical practice to answers from guidelines. 290
Chronic hepatitis C virus infection and atherosclerosis: Clinical impact and mechanisms. 288
The time has come to look for metabolic dysfunction-associated fatty liver disease in adult patients with type 1 Gaucher disease 281
Role of Multidrug-Resistance Protein 2 in coproporphyrin transport: results from experimental studies in bile fistula rat models 277
Alcohol and Steatosis: The Japanese Paradox 275
Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases 274
Pathogenesis and significance of hepatitis C virus steatosis: An update on survival strategy of a successful pathogen 273
A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue? 272
Association between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis 269
Global multi-stakeholder endorsement of the MAFLD definition 266
Hypothyroidism and nonalcoholic fatty liver disease - A chance association? 259
Association of nonalcoholic fatty liver disease (Nafld) with peripheral diabetic polyneuropathy: A systematic review and meta-analysis 258
Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study 252
Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? 251
Nonalcoholic steatohepatitis heralding olmesartan-induced sprue-like enteropathy 250
Energy balance, glucose and lipid metabolism, cardiovascular risk and liver disease burden in adult patients with type 1 Gaucher disease 250
Liver steatosis is highly prevalent and is associated with metabolic risk factors and liver fibrosis in adult patients with type 1 Gaucher disease 249
Pathogenesis of hypothyroidism-induced NAFLD: Evidence for a distinct disease entity? 242
Type 2 diabetes in non-alcoholic fatty liver disease and hepatitis c virus infection—liver: The “Musketeer” in the spotlight 230
Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications 229
Insulin resistance in advanced liver cirrhosis : the role of liver dysfunction and the “dissociated” effect on glucose versus lipid and amino acid metabolism 226
Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease 224
Telomere shortening: An innocent bystander at the crossroad of NASH with ageing and cardiometabolic risk? 220
La fibrosi epatica: aggiornamenti su fisiopatologia, diagnosi e prognosi 215
A case of statin-induced liver injury with positive rechallenge with a second statin. Is there a class effect? 215
Nonalcoholic fatty liver disease and COPD: is it time to cross the diaphragm? 212
Inflammatory hepatocellular adenomatosis, metabolic syndrome, polycystic ovary syndrome and non-alcoholic steatohepatitis: Chance tetrad or association by necessity? 211
Hyperferritinemia and diagnosis of type 1 Gaucher disease 205
Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease 203
Do ultrasonographic semiquantitative indices predict histological changes in NASH irrespective of steatosis extent? 199
COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs 197
The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans 192
Sex Differences in NAFLD: State of the Art and Identification of Research Gaps 188
The genetic basis of Insulin resistance. A brief review 187
Non-alcoholic fatty liver disease: Diagnosis and investigation 178
The independent predictors of non-alcoholic steatohepatitis and its individual histological features.: Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment 178
Looking for women in hepatology: Sex authorship differences in clinical practice guidelines and position statements 178
Contemporary lipid-lowering management and risk of cardiovascular events in homozygous familial hypercholesterolaemia: insights from the Italian LIPIGEN Registry 173
Significant variations in elastometry measurements made within short-term in patients with chronic liver diseases 173
Liver involvement in Gaucher disease: A practical review for the hepatologist and the gastroenterologist 173
Hepatic and extrahepatic malignancies in NAFLD 169
Frailty after Liver Transplantation: A Complex Unexplored Issue 168
Clinical Approach in the Management of Paediatric Patients with Familial Hypercholesterolemia: A National Survey Conducted by the LIPIGEN Paediatric Group 167
NAFLD, Hepatotropic Viruses, and Cardiometabolic Risk 167
Lipidomic profiling of MASLD: identifying lipid biomarkers for detection and stratification of disease severity 161
Identifying lipid patterns through lipidomic profiling for MASLD detection and severity stratification 155
Mapping the lipid landscape of MASLD: insights into disease progression through lipidomic patterns 152
Is it time to include non-alcoholic fatty liver disease in the current risk scores for atrial fibrillation? 149
Colon cancer in a 12-year-old girl with hypertriglyceridemia 148
Metabolic Disorders in Liver Transplant Recipients: The State of the Art 138
AISF update on the diagnosis and management of adult-onset lysosomal storage diseases with hepatic involvement 138
Refinement of the diagnostic approach for the identification of children and adolescents affected by familial hypercholesterolemia: Evidence from the LIPIGEN study 135
Lipoprotein(a) Genotype Influences the Clinical Diagnosis of Familial Hypercholesterolemia 133
Liver fibrosis biomarkers accurately exclude advanced fibrosis and are associated with higher cardiovascular risk scores in patients with NAFLD or viral chronic liver disease 131
Liver transplantation and nonalcoholic steatohepatitis: the state of the art 125
Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease 118
Enzyme replacement therapy improves erythropoiesis and iron dysregulation in Gaucher disease 107
Extra-hepatic manifestations and complications of nonalcoholic fatty liver disease 105
Achilles tendon ultrasonography in familial hypercholesterolemia: A sub-study of the LIpid transPort disorders Italian GEnetic Network (LIPIGEN) 98
Splenomegaly: Dare to think rare 89
Diagnostic Accuracy of Golgi Protein 73 (GP73) for Liver Fibrosis Staging in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Scoping Review and Cohort Study 78
Identifying possible homozygous familial hypercholesterolemia patients: An Italian experts' opinion 73
Diagnosis and Screening Strategies for Detection of Familial Hypercholesterolaemia in Children and Adolescents in Italy: A Survey from the LIPIGEN Paediatric Group 71
Diagnosi e storia naturale della steatosi epatica non alcolica. Performance e limiti delle tecniche diagnostiche invasive e non invasive e risultati del follow-up a lungo termine delle cirrosi criptogenetiche. 66
Real-world management of familial hypercholesterolemia in paediatric patients: a 3-year follow-up from the LIPIGEN registry 12
Totale 20.570
Salva come PNG Salva come JPEG
Categoria #
all - tutte 75.297
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 75.297
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.340 102 118 65 77 83 112 45 53 163 149 247 126
2022/20231.407 133 173 140 123 150 176 27 149 175 17 66 78
2023/2024829 34 53 79 69 162 75 56 82 22 23 56 118
2024/20253.350 82 46 99 191 613 447 319 215 342 201 357 438
2025/20267.938 440 279 583 856 1.108 766 977 373 792 667 523 574
2026/2027258 258 0 0 0 0 0 0 0 0 0 0 0
Totale 20.570